MammoLink, a physician-owned provider of mobile 3D mammography services, has added CureMetrix’s cmAngio to its breast imaging programme.
MammoLink delivers screening mammography directly to communities, employers, physician offices and healthcare partners across Florida.
“At MammoLink, our mission has always been to make high-quality breast imaging more accessible while maximising the value of every screening mammogram,” said Dr Ryan Polselli, founder and breast imaging radiologist at MammoLink.
“Adding cmAngio allows us to provide additional clinical insight from the same exam women are already receiving. It’s a simple way to enhance patient care without adding time, radiation, or complexity to the screening experience.”
cmAngio is an FDA-cleared solution to detect, quantify and contextualise breast arterial calcifications (BAC). It identifies BAC from the routine screening mammogram, without additional imaging, radiation, procedures or changes to standard mammography workflows.
“Mobile mammography is a rapidly growing segment of the screening mammography market and delivers a critical service to underserved, rural, and hard to reach women,” said CureMetrix president Kevin Harris. “By incorporating cmAngio into their program, MammoLink is maximizing the experience and value for these women and turning their mammograms into a 2-for-1 exam”.
